Entrada Therapeutics Inc (TRDA)
18.05
+0.12
(+0.67%)
USD |
NASDAQ |
Nov 21, 16:00
18.08
+0.02
(+0.14%)
After-Hours: 20:00
Entrada Therapeutics Revenue (Quarterly): 19.57M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
Date | Value |
---|---|
September 30, 2024 | 19.57M |
June 30, 2024 | 94.69M |
March 31, 2024 | 59.12M |
December 31, 2023 | 41.85M |
Date | Value |
---|---|
September 30, 2023 | 43.74M |
June 30, 2023 | 18.17M |
March 31, 2023 | 25.26M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
18.17M
Minimum
Jun 2023
94.69M
Maximum
Jun 2024
43.20M
Average
41.85M
Median
Dec 2023
Revenue (Quarterly) Benchmarks
Catalyst Pharmaceuticals Inc | 128.70M |
Vertex Pharmaceuticals Inc | 2.772B |
Assembly Biosciences Inc | 6.845M |
Sarepta Therapeutics Inc | 467.17M |
Regenxbio Inc | 24.20M |
Revenue (Quarterly) Related Metrics
Net Income (Quarterly) | -14.03M |
Total Expenses (Quarterly) | 41.23M |
EPS Diluted (Quarterly) | -0.35 |
Enterprise Value | 226.09M |
Profit Margin (Quarterly) | -71.70% |
Earnings Yield | 8.81% |
Operating Earnings Yield | 8.87% |
Normalized Earnings Yield | 8.809 |